Metaflam Oral Suspension
$ 38,00 – $ 77,00Price range: $ 38,00 through $ 77,00
Namenda
$ 42,00 – $ 174,00Price range: $ 42,00 through $ 174,00
Mirapex
$ 30,00 – $ 440,00Price range: $ 30,00 through $ 440,00
Mirapex is a specialized medication primarily used to manage the symptoms of Parkinson’s disease and moderate-to-severe Restless Legs Syndrome. This treatment functions as a dopamine agonist, helping to restore the balance of natural substances in the brain responsible for movement. Patients often rely on this formula to reduce tremors, muscle stiffness, and slowed movements associated with Parkinson’s. Additionally, it effectively alleviates the persistent urge to move the legs and the uncomfortable sensations often felt during periods of rest. By supporting neurological function, Mirapex helps individuals maintain better physical control and improve their overall daily comfort.
SKU:
Mirapex
Category: Other
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM
Each dosage option has its own packaging choices.
Description
Mirapex belongs to a class of medications known as non-ergot dopamine agonists. It is an FDA-approved prescription medication indicated for the management of signs and symptoms associated with idiopathic Parkinson’s disease and moderate-to-severe primary Restless Legs Syndrome (RLS). Clinical administration requires individual titration under the direct supervision of a licensed healthcare provider.
The following technical summary provides an overview of the pharmacological characteristics, therapeutic applications, safety warnings, and clinical considerations for Mirapex based on official prescribing information.
Basic Information
| Parameter | Details |
|---|---|
| Active Ingredient | Pramipexole dihydrochloride |
| Prescription Status | Prescription only (Rx) |
| Route of Administration | Oral |
| Primary Indications | Parkinson’s disease, Restless Legs Syndrome (RLS) |
| Dosage Form | Immediate-release oral tablets |
| Storage Conditions | Controlled room temperature (20°C to 25°C / 68°F to 77°F) |
How the Drug Works
Pramipexole is a non-ergot dopamine agonist with high selective affinity for the D2 subfamily of dopamine receptors. Pharmacodynamic studies demonstrate that pramipexole exhibits higher relative binding affinity for D3 receptors compared to D2 or D4 receptor subtypes. By directly stimulating post-synaptic dopamine receptors within the striatum, Mirapex mitigates the functional deficits caused by the loss of endogenous nigrostriatal dopaminergic neurons in Parkinson’s disease. The precise mechanism by which the drug exerts its therapeutic effect in Restless Legs Syndrome is not fully elucidated, but it is believed to involve stimulation of central dopamine pathways regulating motor activity and sensorimotor integration.
Main Uses
Mirapex is FDA-approved for the treatment of the signs and symptoms of idiopathic Parkinson’s disease. It may be prescribed as initial monotherapy in early stage disease to delay the introduction of levodopa, or as adjunctive therapy in combination with levodopa in advanced stages to reduce “off” periods and motor fluctuations. Additionally, immediate-release Mirapex is FDA-approved for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS). Any application outside of these specific FDA-approved indications, such as the treatment of bipolar depression or treatment-resistant major depressive disorder, is classified as an off-label use and requires clinical evaluation by a specialized prescriber.
Dosing Schedule
Mirapex is administered orally in tablet form. Dosing regimens must be individualized based on clinical response and tolerability. To minimize the incidence of dose-dependent adverse effects, such as orthostatic hypotension, nausea, and somnolence, treatment must be initiated at low doses and escalated gradually at weekly intervals.
- Parkinson’s Disease: Therapy typically commences at 0.125 mg three times daily (0.375 mg total daily dose) and is gradually increased no more frequently than every 5 to 7 days, up to a maximum recommended total daily dose of 4.5 mg.
- Restless Legs Syndrome: The standard initial dose is 0.125 mg taken once daily 2 to 3 hours before bedtime. Escalation may occur every 4 to 7 days up to a maximum daily dose of 0.54 mg.
Because pramipexole is excreted primarily via renal filtration, dosage adjustments are necessary for patients with moderate to severe renal impairment based on calculated creatinine clearance values.
What Happens in the Body
Pramipexole is rapidly and extensively absorbed following oral administration. Absolute bioavailability exceeds 90%, reflecting minimal first-pass metabolism. Peak plasma concentrations are typically achieved within 1 to 3 hours after administration under fasting conditions. Administration with food does not alter the overall extent of absorption (AUC), although it may delay the peak plasma concentration (Tmax) by approximately 1 hour.
Pramipexole is widely distributed throughout body tissues, with an apparent volume of distribution of approximately 500 liters. Plasma protein binding is minimal, measured at less than 20%. The drug undergoes negligible hepatic metabolism, with approximately 90% of an administered dose recovered unchanged in the urine. The terminal elimination half-life is approximately 8 hours in young healthy subjects and extends to approximately 12 hours in elderly individuals or patients with impaired kidney function.
Compatibility with Other Medicines
Pramipexole is cleared mainly through renal tubular secretion via the organic cation transport system. Concomitant administration of drugs that inhibit or compete for active renal cationic secretion–such as cimetidine, ranitidine, diltiazem, triamterene, verapamil, or quinidine–may reduce the renal clearance of pramipexole, resulting in increased systemic exposure.
Dopamine antagonists, including neuroleptic agents (e.g., haloperidol, chlorpromazine, thioridazine) and metoclopramide, may diminish the therapeutic efficacy of Mirapex due to receptor blockade. Co-administration with central nervous system (CNS) depressants or sedative substances can produce additive sedative effects and increase the risk of pronounced somnolence.
Adverse Reactions
Adverse reactions observed during clinical trials vary based on the primary indication and concurrent anti-Parkinsonian therapy. Common adverse reactions in patients with early Parkinson’s disease receiving monotherapy include nausea, dizziness, somnolence, insomnia, constipation, asthenia, and hallucinations.
In patients with advanced Parkinson’s disease receiving concomitant levodopa, adverse reactions occur with higher frequency and include dyskinesia, orthostatic hypotension, extrapyramidal symptoms, confusion, accidental injury, and peripheral edema. Patients treated with dopamine agonists, including Mirapex, have experienced impulse control disorders, such as compulsive gambling, hypersexuality, binge eating, and uncontrollable purchasing behaviors. Sudden onset of sleep (“sleep attacks”) during daily activities without preceding awareness or warning signs has also been documented.
Important Precautions
Abrupt cessation of dopamine agonist therapy can lead to a symptom complex resembling neuroleptic malignant syndrome, characterized by hyperpyrexia, muscle rigidity, altered consciousness, and autonomic instability. Discontinuation of Mirapex must occur through a gradual dose-tapering schedule under physician oversight.
Patients with severe renal insufficiency require careful monitor and modified dosing intervals. In elderly patients, the incidence of cognitive disturbances and visual hallucinations is higher. Mirapex should be used during pregnancy only if the potential clinical benefit justifies the potential risk to the fetus. It is unknown whether pramipexole is excreted in human milk; however, because dopamine agonists inhibit prolactin secretion, inhibition of lactation is anticipated.
First Days of Treatment
During the initial phase of therapy, patients may not notice immediate relief of symptoms because the medication requires careful, stepwise dose titration to reach a therapeutic level. Mild nausea and transient postural lightheadedness are common early responses as the body adapts to dopaminergic stimulation. Taking the dose with light food can assist in mitigating initial gastrointestinal upset. Close observation by patients and caregivers regarding daytime alertness and behavioral shifts is recommended during the first weeks of treatment.
Missed Dose
If a dose of Mirapex is missed, it should be taken as soon as remembered, unless the time is close to the next scheduled administration. Patients should not double the dose to compensate for a missed tablet. Re-establishing regular dosing intervals preserves steady-state plasma concentrations and reduces symptom fluctuation.
Food and Alcohol Interactions
Mirapex can be taken with or without food. Co-ingestion with meals reduces the rate, but not the extent, of absorption and may decrease the severity of nausea. Alcohol consumption should be avoided during Mirapex therapy, as ethanol enhances central nervous system depression, potentially increasing drowsiness, dizziness, and the risk of postural hypotension.
Practical Tips
Patients should transition slowly when moving from a sitting or lying position to standing to reduce the risk of orthostatic dizziness. Caution must be exercised when operating motor vehicles or machinery until the patient’s individual response to Mirapex and level of alertness are clearly established. Caregivers should monitor for emerging impulse control behaviors and notify the prescriber promptly if unusual urges develop.
Common Questions
Can Mirapex cause sudden daytime sleepiness?
Yes. Mirapex has been associated with somnolence and episodes of sudden sleep onset during routine activities, including driving. Patients experiencing significant daytime drowsiness should refrain from driving or engaging in potentially hazardous tasks and report these symptoms to their physician.
How should Mirapex be stopped if discontinuation is necessary?
Mirapex must never be stopped abruptly. Tapering the daily dose gradually under direct medical guidance is necessary to minimize the risk of dopamine agonist withdrawal syndrome or symptoms resembling neuroleptic malignant syndrome.
Is Mirapex safe to use during pregnancy?
The safety of Mirapex during human pregnancy has not been established in adequate and well-controlled studies. Mirapex should be prescribed during pregnancy only when the potential benefits outweigh the potential risks to the developing fetus.
What should be done if impulse control disorders occur?
If a patient demonstrates unusual or compulsive behaviors–such as pathological gambling, excessive eating, or compulsive shopping–a healthcare professional should be contacted immediately. Dose reduction or gradual discontinuation of the medication typically resolves these behaviors.
Does Mirapex interact with medications used for high blood pressure?
Mirapex can cause orthostatic hypotension. When combined with antihypertensive agents, additive blood-pressure-lowering effects may occur, requiring regular monitoring of blood pressure and potential dosage adjustments by a physician.
In accordance with FDA requirements.
This text is for informational purposes only and does not constitute individual medical advice.
Additional information
| Dosage |
0.125 mg ,0.25 mg ,0.5 mg ,1 mg |
|---|---|
| Package |
30 pills ,60 pills ,90 pills ,180 pills |
| Active Ingredient |
Pramipexole |
Related products
Amalaki
$ 42,00 – $ 72,00Price range: $ 42,00 through $ 72,00
Active substance: Amalaki (Emblica officinalis) Extract
More Details
This product has multiple variants. The options may be chosen on the product page
Arcalion
$ 25,00 – $ 50,00Price range: $ 25,00 through $ 50,00
Active substance: Sulbutiamine
More Details
This product has multiple variants. The options may be chosen on the product page
Carbocisteine
$ 45,00 – $ 65,00Price range: $ 45,00 through $ 65,00
Active substance: Carbocisteine
More Details
This product has multiple variants. The options may be chosen on the product page
DDAVP spray
$ 64,00 – $ 412,00Price range: $ 64,00 through $ 412,00
Active substance: Desmopressin acetate
More Details
This product has multiple variants. The options may be chosen on the product page
Imusporin
$ 117,00 – $ 535,00Price range: $ 117,00 through $ 535,00
Active substance: Cyclosporine
More Details
This product has multiple variants. The options may be chosen on the product page
LDN
$ 81,00 – $ 266,00Price range: $ 81,00 through $ 266,00
Active substance: Naltrexone
More Details
This product has multiple variants. The options may be chosen on the product page
Levothroid
$ 42,00 – $ 144,00Price range: $ 42,00 through $ 144,00
Active substance: Levothyroxine sodium
More Details
This product has multiple variants. The options may be chosen on the product page
Limcee
$ 21,00 – $ 39,00Price range: $ 21,00 through $ 39,00
Active substance: Ascorbic Acid
More Details
This product has multiple variants. The options may be chosen on the product page
